NCT01485536View on ClinicalTrials.gov

A Study of the HSP90 Inhibitor AUY922

PHASE2TerminatedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Lymphoma

Interventions

DRUG

AUY922

Starting Dose: 70 mg/m2 by vein on days 1, 8, 15, and 22 days of a 28 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER